# Study Comparing Simulect Plus Standard Immunosuppression to Standard Immunosuppression Alone for the Prevention of Acute Rejection and Bronchiolitis Obliterans in Lung Transplant

> **NCT00188825** · PHASE3 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 22 (actual)

## Conditions studied

- COPD
- Emphysema
- Alpha-1 Antitrypsan Deficiency

## Interventions

- **OTHER:** placebo
- **DRUG:** basiliximab

## Key facts

- **NCT ID:** NCT00188825
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2017-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00188825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00188825, "Study Comparing Simulect Plus Standard Immunosuppression to Standard Immunosuppression Alone for the Prevention of Acute Rejection and Bronchiolitis Obliterans in Lung Transplant". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00188825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*